Back
Open Access

Renal benefits of SGLT2 inhibitors in HF patients.

Session: SGLT2 inhibition in heart failure: what have we learned so far?
Topic: Heart Failure
Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Sponsored by Charité Berlin - Supported by an unrestricted educational grant from The Boehringer Ingelheim and Lilly Alliance
Event: Heart Failure 2021 Online Congress

Presentation

0

About the speaker

Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)
69 presentations
0 follower

5 more presentations in this session

Introduction: SGLT2 inhibitors beyond glycemic control.

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Access
Video
0
Thumbnail

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Speaker: Doctor M. Packer (Dallas, US)

Access
Video
0
Thumbnail

Effects of SGLT2 inhibitors on quality of life in HF.

Speaker: Professor J. Butler (Jackson, US)

Access
Video
0
Thumbnail

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Speaker: Professor G. Filippatos (Athens, GR)

Access
Video
0
Thumbnail

Conclusion.

Speaker: Professor S. Anker (Berlin, DE)

Access
Video
0
Thumbnail

Access the full session

SGLT2 inhibition in heart failure: what have we learned so far?

Speakers: Professor F. Zannad, Doctor S. Zieroth, Doctor M. Packer, Professor J. Butler, Professor G. Filippatos...
Access
Video
0
Thumbnail

About the event

Image

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Congress
logo Image

Related content

Open Access

Hot topics in atrial fibrillation.

5 April 2022

ACVC Premium Access

Cardiogenic shock: state of the art 2022 - discussion.

19 March 2022

ACVC Premium Access

Pharmacological treatment: how to choose your drug (if any)

19 March 2022

This platform is supported by

logo Novo Nordisk